Investors & Media Company Overview UNITY Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as ophthalmologic and neurologic diseases. Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Latest Presentation Download News Releases November 4, 2020 UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates October 12, 2020 UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
November 4, 2020 UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates
October 12, 2020 UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
